The latest news: Musella Foundation Copayment Assistance program has reopened! We don't have much funding so it may close quickly. If you are interested, get in your paperwork quickly. It is first come first served. Novocure Announces CE Mark and First Patient Use of Second Generation Optune System The second generation Novocure device is now available in Europe. Hopefully will get FDA approval to use it in the USA soon! It is half the size and weight of the old system, and looks a lot better! With $55M, Neon Wants To Make the Cancer Vaccine “Problem” Personal Talks about a new approach, including a new trial that is already open for newly diagnosed GBM that has unmethylated MGMT. For details on that trial, go to https://clinicaltrials.gov/ct2/show/NCT02287428 Multicenter study shows Monteris’ NeuroBlate System improves outcome in brain tumor patients This is a relatively new, FDA approved robotic laser surgery. This article mentions the ability to target tumors in very hard to reach areas. Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer Very exciting trial. DNX-2401 is an oncolytic virus that had some success alone with GBMs - they reportedly even had 3 complete responses (out of 37 patients). At last report, these 3 patients are still alive and have no evidence of disease 3.2, 2, and 1.75 years after treatment - See details at: http://www.onclive.com/conference-coverage/sno-2014/Oncolytic-Virus-Shows-Early-Promise-in-Glioma#sthash.CQvVJ6Pr.dpuf This used to be called Delta-24-RGD-4C. Keytruda is a checkpoint inhibitor which has the potential to reverse the immune inhibition that GBMs have. Combining these 2 treatments might make a major breakthrough. When the oncolytic virus kills a tumor cell, the Keytruda might allow the body's immune system to recognize and learn from the dead gbm cells and to kill the living GBM cells. BrainTumor Co-Payment Assistance Program Status: OPEN to new applicants
